<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1611">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03420807</url>
  </required_header>
  <id_info>
    <org_study_id>071317</org_study_id>
    <nct_id>NCT03420807</nct_id>
  </id_info>
  <brief_title>Retinal Metabolic Imaging of Alzheimer Patient</brief_title>
  <official_title>Evaluation of Beta-amyloid Plaques of the Retina Using Metabolic Hyperspectral Retinal Camera (MHRC) in Alzheimer's Patients - Toronto Study Arm</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Optina Diagnostics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>McGill University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Polytechnique Montreal</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sunnybrook Health Sciences Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Optina Diagnostics Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research project concerns the evaluation of the Metabolic Hyperspectral Retinal Camera&#xD;
      (MHRC), a novel medical instrument from Optina Diagnostics, for the detection of beta-amyloid&#xD;
      plaques, a hallmark of Alzheimer's disease (AD), in the retina. The experimental device,&#xD;
      produces multiple images of the retina when subjected to light in very specific colors&#xD;
      (90-100 specific colors typically) and may be used to identify specific biomarkers based on&#xD;
      their unique spectral signature. The retina is an extension of the brain and is the only&#xD;
      optically accessible nervous tissue. The MHRC could represent a simple and non-invasive tool&#xD;
      to facilitate the diagnosis of AD.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Alzheimer's disease (AD), a neurodegenerative disorder characterized by cognitive impairment&#xD;
      and a suspected dementia syndrome, is the most common type of dementia (&gt;50% of all cases),&#xD;
      affecting millions worldwide, with no cure available at this time. Definite AD diagnosis&#xD;
      currently relies on the post-mortem observation of the hallmarks β-amyloid peptides (Aβ)&#xD;
      extracellular aggregates, Aβ plaques, and protein tau intracellular twisted strands&#xD;
      (neurofibrillary tangles, NFTs). Earlier diagnosis could dramatically transform the design&#xD;
      and execution of clinical trials to test new treatments. The eye offers a natural window to&#xD;
      the brain as the retina, the light sensitive layer lining the interior of the eye is an&#xD;
      extension of the brain. The presence of Aβ plaques in the retina of AD mice models and humans&#xD;
      was recently reported opening the possibility of detecting this AD hallmark though a simple&#xD;
      non-invasive eye scan. The proposed research aims to explore this avenue with the development&#xD;
      of a spectrally-resolved optical retinal imaging platform to detect Aβ plaques in the retina&#xD;
      of AD subjects and validate the method against brain Aβ plaques seen on amyloid PET imaging.&#xD;
      The novel imaging platform is expected to help aid the early detection of AD and assist in&#xD;
      monitoring efficacy of possible future therapeutic agents that target relevant molecular&#xD;
      pathways.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">December 4, 2017</start_date>
  <completion_date type="Anticipated">September 26, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 26, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Subjects will undergo 1) clinical characterization, 2) ophthalmic evaluation, 3) evaluation with the device (camera) and 4) brain imaging session (MRI + amyloid PET).</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Retinal beta-amyloid detection</measure>
    <time_frame>Within 21 days following clinical characterization completion</time_frame>
    <description>Presence of absence of beta-amyloid plaques in the retina</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>MHRC camera</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will undergo a retina imaging session with the MHRC camera.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MHRC</intervention_name>
    <description>Evaluate the feasibility of detection of beta-amyloid plaques by using their spectral signature in autofluorescence or reflectance.</description>
    <arm_group_label>MHRC camera</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects with Alzheimer's disease&#xD;
&#xD;
               -  Meet criteria for probable, possible Alzheimer's disease by McKhann criteria&#xD;
                  (McKhann et al. 2011)&#xD;
&#xD;
               -  Mini-Mental State Examination score between 20 and 27 (inclusive)&#xD;
&#xD;
               -  Vascular load scale ≤ 4 (Hachinski Ischaemia Score)&#xD;
&#xD;
               -  Sufficient degree of cooperation to undergo all examinations&#xD;
&#xD;
               -  Availability of a reliable responsible study partner to accompany the patient to&#xD;
                  the appointments&#xD;
&#xD;
          2. Subjects with Mild Cognitive Impairment&#xD;
&#xD;
               -  Meet criteria for amnestic single or multi domain Mild Cognitive Impairment&#xD;
                  (without crossing the threshold for dementia)&#xD;
&#xD;
               -  No signs of systemic, neurologic or psychiatric disorders that can cause&#xD;
                  cognitive deficits&#xD;
&#xD;
               -  Scores on cognitive tests: 1 to 1.5 standard deviation below the mean of their&#xD;
                  age and education matched peers&#xD;
&#xD;
               -  Diagnosis that follows Albert criteria (Albert et al. 2011)&#xD;
&#xD;
          3. Healthy control subjects&#xD;
&#xD;
               -  No clinical signs of dementia&#xD;
&#xD;
               -  Telephone Mini-Mental State Examination score ≥ 25 or&#xD;
&#xD;
               -  MoCA ≥ 26&#xD;
&#xD;
               -  Behavioural Neurology Assessment-R (BNA-R; Annex IX; within limits on all sub&#xD;
                  tests)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of one or more contraindications (PET and/or MRI)&#xD;
&#xD;
          -  Presence of glaucoma or retinopathy (diabetic, macular degeneration)&#xD;
&#xD;
          -  Pupil dilation inadequate or contraindicated&#xD;
&#xD;
          -  Deficient visual fixation&#xD;
&#xD;
          -  Refractive error outside the range -9 to +9&#xD;
&#xD;
          -  Impossibility of obtaining satisfactory, quality images with MHRC&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandra Black, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sunnybrook Health Sciences Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David Lapointe</last_name>
    <phone>438-828-1675</phone>
    <email>dlapointe@optinadx.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anne-Marie Bedard</last_name>
    <phone>514-394-0797</phone>
    <email>ambedard@optinadx.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vito Losito</last_name>
      <phone>416-480-6100</phone>
      <phone_ext>85479</phone_ext>
      <email>vito.losito@sri.utoronto.ca</email>
    </contact>
    <contact_backup>
      <last_name>Hossam Elshahawy</last_name>
      <phone>416-480-6100</phone>
      <phone_ext>3497</phone_ext>
      <email>hossam.elshahawy@sunnybrook.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Sandra Black, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mario Masellis, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Benjamin Lam, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Peter Kertes, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Natha Herrmann, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sarah Sarah, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>January 29, 2018</study_first_submitted>
  <study_first_submitted_qc>January 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2018</study_first_posted>
  <last_update_submitted>September 26, 2019</last_update_submitted>
  <last_update_submitted_qc>September 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

